211 related articles for article (PubMed ID: 19191294)
1. Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: the utility of immunocytochemical panel in the differential diagnosis.
Saleh HA; El-Fakharany M; Makki H; Kadhim A; Masood S
Diagn Cytopathol; 2009 May; 37(5):324-32. PubMed ID: 19191294
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
3. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
4. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks.
Kim JH; Kim GE; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
Diagn Cytopathol; 2009 Apr; 37(4):258-61. PubMed ID: 19217030
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
Hyun TS; Barnes M; Tabatabai ZL
Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
[TBL] [Abstract][Full Text] [Related]
8. Discriminating hepatocellular carcinoma from metastatic carcinoma on fine-needle aspiration biopsy of the liver: the utility of immunocytochemical panel.
Saleh HA; Aulicino M; Zaidi SY; Khan AZ; Masood S
Diagn Cytopathol; 2009 Mar; 37(3):184-90. PubMed ID: 19170172
[TBL] [Abstract][Full Text] [Related]
9. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
Su XY; Li GD; Liu HB; Jiang LL
Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
[TBL] [Abstract][Full Text] [Related]
10. Immunocytochemical panel for distinguishing carcinoma cells from reactive mesothelial cells in pleural effusions.
Wu GP; Zhang SS; Fang CQ; Liu SL; Wang EH
Cytopathology; 2008 Aug; 19(4):212-7. PubMed ID: 18699986
[TBL] [Abstract][Full Text] [Related]
11. HBME-1 immunostaining in reactive mesothelial versus metastatic adenocarcinoma cells in serous fluid.
Rahmani A; Dehghani MZ; Afshar NM; Heidarian H; Tahririan R
Indian J Pathol Microbiol; 2011; 54(3):460-3. PubMed ID: 21934203
[TBL] [Abstract][Full Text] [Related]
12. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
Ko EC; Jhala NC; Shultz JJ; Chhieng DC
Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
[TBL] [Abstract][Full Text] [Related]
13. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks.
Bhalla R; Siddiqui MT; Mandich D; Cartun RW; Fiel-Gan MD; Nassar A; Mandavilli SR
Diagn Cytopathol; 2007 Jun; 35(6):342-7. PubMed ID: 17497664
[TBL] [Abstract][Full Text] [Related]
15. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
16. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion.
Ueda J; Iwata T; Ono M; Takahashi M
Diagn Cytopathol; 2006 Jan; 34(1):6-10. PubMed ID: 16355377
[TBL] [Abstract][Full Text] [Related]
17. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations.
Wieczorek TJ; Krane JF
Cancer; 2000 Oct; 90(5):312-9. PubMed ID: 11038429
[TBL] [Abstract][Full Text] [Related]
19. [Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies].
Chenard-Neu MP; Kabou A; Mechine A; Brolly F; Orion B; Bellocq JP
Ann Pathol; 1998 Dec; 18(6):460-5. PubMed ID: 10051912
[TBL] [Abstract][Full Text] [Related]
20. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.
Ruitenbeek T; Gouw AS; Poppema S
Arch Pathol Lab Med; 1994 Mar; 118(3):265-9. PubMed ID: 8135629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
